Document is current

Any future updates will be listed below

Tumor microenvironment delineates differential responders to trastuzumab emtansine in HER2-positive metastatic breast cancer patients previously treated with pyrotinib: an exploratory biomarker analysis of a phase II study (NJMU-BC02)

Crossref DOI link: https://doi.org/10.1038/s41392-025-02409-2

Published Online: 2025-09-29

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark